Teleflex beats quarterly profit estimates on robust medical devices demand
Oct 31 (Reuters) -Surgical equipment maker Teleflex TFX.N reported a better-than-expected profit for the third quarter on Thursday, helped by strong demand for its medical devices.
Robust demand for non-urgent procedures, especially among older adults, have kept investor expectations heightened around the performance of medical device makers over the past year.
Peers such as Boston Scientific BSX.N and Stryker SYK.N have raised their full-year profit forecasts on resilient demand.
Teleflex, which makes types of catheters and pumps, reported a 2.4% rise in third-quarter revenue to $764.4 million, but missed analysts' estimate of $769.6 million, according to data compiled by LSEG.
CEO Liam Kelly said strong sales of the company's bloodstream-related products as well as its heart and medical imaging devices helped offset some "unexpected softness" in OEM revenues.
Sales at the vascular access segment, through which Teleflex makes medical devices for bloodstream-related procedures, rose 6.5% to $180.9 million.
The OEM segment, which designs and manufactures instruments for other medical device makers, reported a marginal rise in sales to $82.6 million.
On an adjusted basis, the company earned $3.49 per share in the quarter ended Sept. 30, beating estimates of $3.39 per share.
Teleflex now expects its annual revenue to grow between 2.9% and 3.4%, down from 3.4% to 4.4% growth previously expected.
The Wayne, Pennsylvania-based company also raised the lower end of its 2024 adjusted per-share profit forecast to $13.90 from $13.80 previously, while keeping the upper end at $14.20.
Reporting by Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
